
We Claim:

1. N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 having the following structure



3. A pharmaceutical composition comprising (i) a compound of claim 1 or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient, diluent, or carrier.

4. The composition of Claim 3 wherein said compound or said pharmaceutically acceptable salt thereof is present in a therapeutically effective amount.

5. The composition of Claim 4 further comprising at least one additional pharmaceutical agent selected from the group consisting of an anti-obesity agent and an anti-diabetic agent.

~~6. The composition of Claim 5 wherein said anti-obesity agent is selected from the group consisting of dirlotapide, mitratapide, implitapide, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorcaserin, cetilistat, PYY_{3-36}, naltrexone, oleoyl-estrone, obinepitide, pramlintide, tesofensine, leptin, liraglutide, bromocriptine, orlistat, exenatide, AOD-9604 (CAS No. 221231-10-3) and sibutramine.~~

~~7. The composition of Claim 5 wherein said anti-diabetic agent is selected from the group consisting of metformin, acetohexamide, chlorpropamide, diabinese,~~

~~glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, tolbutamide, tendamistat, trestatin, acarbose, adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, salbostatin, balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone, troglitazone, exendin-3, exendin-4, trodusquemine, reservatrol, hyrtiosal extract, sitagliptin, vildagliptin, alogliptin and saxagliptin.~~

~~8~~6. The use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment obesity and obesity-related disorders in animals.

~~9~~7. The use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or delaying the progression or onset of Type 2 diabetes and diabetes-related disorders in animals.